Monday, 23 Jul 2018

You are here

Five Barriers to Biosimilar Adoption in the US

A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.

A 2017 analysis from Rand Corporation estimates that biosimilars in the US could trim direct spending on biologic drugs by $54 billion by 2026 (about 3 percent of total estimated biologic spending over the same period).

As part of the recently passed federal budget, biosimilar manufacturers can now participate in Medicare Part D’s Coverage Gap Discount Program. The discounts do not change the out-of-pocket share consumers pay, but they do reduce the total cost of the drugs paid by the Part D prescription drug plans.

Biosimilars have been used for nearly 10 years in Europe where they have been readily adopted.  In France, the expectation is that over 70% of patients will be prescribed a biosimilar over a biologic. 

The authors propose five challenges that could be keeping biosimilar manufacturers from gaining more traction in the US market:

  1. Pricing: While generic drugs may cost 70 percent less than a branded drug, biosimilar manufacturers have been unable to offer prices that are that much lower than the originator biologic. Thus far, the discounts have not been enough to significantly shift demand away from the branded biosimilar. The entry of multiple biosimilars for the same reference product could lead to steeper discounts (and potentially a price war).
  2. Sales and marketing: Generic manufacturers dont need a sales force to call on physicians, yet they will be necessary and costly to grow biosimilar use, especially with physician reluctance. As physicians become more comfortable with biosimilars, manufacturers that are slower to market could wind up being more profitable than the early movers that invested in sales and physician education. 
  3. Physician acceptance: European physicians tend to be more comfortable prescribing biosimilars than US physicians. This is partly because biosimilars have been available in Europe far longer, physicians there are more familiar and the discounts are sizeable and benefit the cost of healthcare locally.  The question is when will health plans or health systems mandate biosimilars and will they do so at the expense of profits garnered in a rebate driven system for brand biologics. The Food and Drug Administration (FDA) has launched a website, with featured developed educational videos, to give physicians a better understanding of biosimilars as a cost-saving option and to learn more about the approval process for the drugs.
  4. Legal issues: Lawsuits filed by biologic originators against biosimilar manufacturers might also be impeding the growth of biosimilars in the US. Not only can litigation delay the launch of new biosimilars, it also could keep US prices higher compared to those in Europe. Patent litigations against biosimilar manufacturers continue to play a key role in manufacturer defense strategies. Some biologic manufacturers are facing scrutiny over perceived anti-competitive practices aimed at preventing uptake of biosimilars.
  5. Regulatory barriers: Biosimilar substitution guidelines are evolving to favor biosimilar access across markets. A growing number of states have enacted laws that allow a pharmacist to substitute a biosimilar for a prescribed biologic therapy if the biosimilar has been approved by the Food and Drug Administration (FDA) as being interchangeable. So far, FDA hasn’t approved any biosimilar for interchangeability. 

Biosimilars in the US have a long way to go to catch up to Europe. This opportunity may incease as more patents expire for biologic drugs. Nonetheless, biosimilar manufacturers need to develop strategies to break through the biosimilar barriers that exist in the US market.


The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Defining Refractory RA by Biologic Use

A study from the  British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).

IL-23 Inhibitor Fails in Ankylosing Spondylitis

A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.

EULAR 2018 - Day 4 Report

The EULAR 2018 wound down on Saturday with fewer oral presentations but many posters.  In my last report I put together a collection of impressions and some thematic highlights not covered in previous reports. Also some of these represent research and reporting trends – some healthy, others not so – that were evident at the EULAR 2018 meeting.


High Biologic Blood Levels Increases the Risk of Infections in RA

A big concern of most is the risk of infection with use of tumour necrosis factor inhibitor (TNFi) and biologic drugs.  While studied in both trials and in post-marketing studies, it is unknown if infection risk is dose-dependent.

In abstract OP0229 UK researchers have shown high biologic blood levels are associates with an increased risk of total infections in RA, but not serious infetions.

Biosimilar Data at #EULAR2018

Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.